A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms EYEberia
- Sponsors AbbVie; Allergan
Most Recent Events
- 01 Apr 2023 This trial has been Completed in Spain, According to European Clinical Trials Database record.
- 05 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Sep 2022 Planned End Date changed from 30 Aug 2022 to 23 Sep 2025.